Literature DB >> 16409147

Amyloidosis.

Mark B Pepys1.   

Abstract

Amyloidosis is a clinical disorder caused by extracellular deposition of insoluble abnormal fibrils, derived from aggregation of misfolded, normally soluble, protein. About 23 different unrelated proteins are known to form amyloid fibrils in vivo, which share a pathognomonic structure although they are associated with clinically distinct conditions. Systemic amyloidosis, with amyloid deposits in the viscera, blood vessel walls, and connective tissue, is usually fatal and is the cause of about one per thousand deaths in developed countries. This rarity and the variable involvement of different organs and tissues are often responsible for missed or delayed diagnosis, and amyloidosis remains a considerable clinical challenge. However, recent elucidation of important aspects of pathogenesis, as well as developments in diagnosis, monitoring, and treatment, have greatly improved outcomes, especially when patients are managed in specialist centers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409147     DOI: 10.1146/annurev.med.57.121304.131243

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  172 in total

1.  [A tongue biopsy led to the diagnosis].

Authors:  M Brandstetter; Y Matsuba; A Knopf
Journal:  HNO       Date:  2012-05       Impact factor: 1.284

2.  Characterizing the assembly of the Sup35 yeast prion fragment, GNNQQNY: structural changes accompany a fiber-to-crystal switch.

Authors:  Karen E Marshall; Matthew R Hicks; Thomas L Williams; Søren Vrønning Hoffmann; Alison Rodger; Timothy R Dafforn; Louise C Serpell
Journal:  Biophys J       Date:  2010-01-20       Impact factor: 4.033

3.  SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

4.  Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Amyloid       Date:  2010-09       Impact factor: 7.141

5.  A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5.

Authors:  Jonathan S Wall; Tina Richey; Sally Macy; Eric Heidel; Craig Wooliver; Stephen J Kennel
Journal:  Amyloid       Date:  2013-01-17       Impact factor: 7.141

6.  Localized thymic amyloidosis presenting with myasthenia gravis: case report.

Authors:  Seung-Myoung Son; Yong-Moon Lee; Si Wook Kim; Ok-Jun Lee
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

7.  Arresting amyloid with coulomb's law: acetylation of ALS-linked SOD1 by aspirin impedes aggregation.

Authors:  Alireza Abdolvahabi; Yunhua Shi; Nicholas R Rhodes; Nathan P Cook; Angel A Martí; Bryan F Shaw
Journal:  Biophys J       Date:  2015-03-10       Impact factor: 4.033

8.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

Review 9.  Considering protonation as a posttranslational modification regulating protein structure and function.

Authors:  André Schönichen; Bradley A Webb; Matthew P Jacobson; Diane L Barber
Journal:  Annu Rev Biophys       Date:  2013-02-28       Impact factor: 12.981

10.  Computational modeling of the relationship between amyloid and disease.

Authors:  Damien Hall; Herman Edskes
Journal:  Biophys Rev       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.